Micronized drug powders in binary mixtures and the effect of physical properties on aerosolization from combination drug dry powder inhalers

References

• Chougule MB, Padhi BK, Jinturkar KA, Misra A. (2007). Development of dry powder inhalers. Recent Pat Drug Deliv Formul, 1:11–21.
   PubMedGoogle Scholar
• Chan HK. (2006). Dry powder aerosol delivery systems: current and future research directions. J Aerosol Med, 19:21–27.
   PubMedGoogle Scholar
• Pritchard JN. (2001). The influence of lung deposition on clinical response. J Aerosol Med, 14 Suppl 1:S19–S26.
   PubMedGoogle Scholar
• Lalor C, Hickey A. Pharmaceutical aerosols for delivery of drugs to the lungs. Physical and Chemical Properties of Aerosols, Blackie Academic and Professional, London, United Kingdom. 1998:391–428.
   Google Scholar
• Staniforth JN. Pre-formulation aspects of dry powder aerosols. In: RN Dalby, PR Byron, and SJ Farr, Editors, Respiratory drug delivery V. Buffalo Grove, IL: USA; Interpharm Press, 1996.
   Google Scholar
• Yang TTKD. Use of an agglomerate formulation in a new multidose dry powder inhaler. In: RN Dalby, PR Byron, SJ Farr and J Peart, Editors, Respiratory Drug Delivery VII, Raleigh: Serentec Press, 2000.
   Google Scholar
• Young PM, Traini D, Edge S. Advances in Pulmonary Therapy. In: Williams BO, Taft DT, McConville JT, Editors, Advanced drug formulation design to optimize therapeutic outcomes. New York: Informa Healthcare; 2007.1–51.
   Google Scholar
• Salama RO, Young PM, Rogueda P, Lallement A, Iliev I, Traini D. (2011). Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease? Expert Opin Pharmacother, 12:1913–1932.
   PubMed Web of Science ®Google Scholar
• Hannay MGN, Ludzik A, Jansen R, Fletcher I. Overcoming the challenges of developing combination products in different inhalation device platforms. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young, Editors, Respiratory Drug Delivery, Richmond, VA: Virginia Commonwealth University, 2008; 319–328.
   Google Scholar
• Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. (2003). Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol, 112:29–36.
   PubMed Web of Science ®Google Scholar
• Traini D, Adi H, Young PM, Chan HK, Stewart P, Agus H. Cospray dried antibiotics for dry powder lung delivery. J Pharmaceut Sci. 2008;97:3356–3366.
   PubMed Web of Science ®Google Scholar
• Jin FHM, Byron PR. Co-deposition of Albuterol sulphate - Ipratropium bromide co-crystals aerosols. In: RN Dalby, PR Byron, J Peart, JD, Suman, Editors, Respiratory Drug Delivery, Richmond, VA:Virginia Commonweath University, 2007;1:373–6.
   Google Scholar
• Price R, Pitchayajittipong C, Shur J. Engineering of Crystalline Combination Inhalation Particles of a Long-Acting beta(2)-agonist and a Corticosteroid. Pharmaceut Res. 2009;26:2657–2666.
   PubMed Web of Science ®Google Scholar
• El-Gendy N, Berkland C. (2009). Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res, 26:1752–1763.
   PubMed Web of Science ®Google Scholar
• Begat P, Morton DA, Staniforth JN, Price R. (2004). The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy. Pharm Res, 21:1591–1597.
   PubMed Web of Science ®Google Scholar
• Taki M, Marriott C, Zeng X, Martin G, editors. The Aerodynamic Deposition of Drugs from Combination DPI Formulations: The Influence of Particle Size and Drug-Drug and Interactions. Drug Delivery to lungs 19; 2008; Edinburg, Scotland, UK.
   Google Scholar
• Begat P, Morton DA, Staniforth JN, Price R. (2004). The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics. Pharm Res, 21:1826–1833.
   PubMed Web of Science ®Google Scholar
• Young PM, Price R, Tobyn MJ, Buttrum M, Dey F. (2003). Investigation into the effect of humidity on drug-drug interactions using the atomic force microscope. J Pharm Sci, 92:815–822.
   PubMed Web of Science ®Google Scholar
• Rhodes G. Crystallography- Made Crystal Clear.1993.
   Google Scholar
• Larhrib H, Martin GP, Marriott C, Prime D. (2003). The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm, 257:283–296.
   PubMed Web of Science ®Google Scholar
• Nachiengtung. Solid-state characterisation of beclomethasonedipropionate solvates and polymorphs: Purdue;1999.
   Google Scholar
• Matos JR, Felix FS, da Silva LCC, Angnes L. Thermal behavior study and decomposition kinetics of salbutamol under isothermal and non-isothermal conditions. J Therm Anal Calorim. 2009;95:877–880.
   Web of Science ®Google Scholar
• Clark AR, Hollingworth AM. (1993). The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers–implications for in vitro testing. J Aerosol Med, 6:99–110.
   PubMedGoogle Scholar
• Behara S, Larson I, Morton DAV, Stewart P, editors. Effect of time on concentration de-agglomeration and particle size distributions of aerosol clouds generated by a simple marketed device. Meeting on lactose as a carrier for inhalation products; 2010; Parma, Italy: TefarcoInnova, University of Parma, Italy.
   Google Scholar
• BabuBehara SR, Larson I, Kippax P, Morton D, Stewart P. An approach to characterising the cohesive behaviour of powders using a flow titration aerosolisation based methodology. Chemical Engineering Science. 2011.
   Web of Science ®Google Scholar